Cargando…
Lenvatinib resistance mechanism and potential ways to conquer
Lenvatinib (LVN) has been appoved to treat advanced renal cell carcinoma, differentiated thyroid carcinoma, hepatocellular carcinoma. Further other cancer types also have been tried in pre-clinic and clinic without approvation by FDA. The extensive use of lenvastinib in clinical practice is sufficie...
Autores principales: | Bo, Wentao, Chen, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157404/ https://www.ncbi.nlm.nih.gov/pubmed/37153782 http://dx.doi.org/10.3389/fphar.2023.1153991 |
Ejemplares similares
-
YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
por: Guo, Jun, et al.
Publicado: (2021) -
A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
por: Wang, Cong-Cong, et al.
Publicado: (2023) -
Pain after thoracotomy: Conquered or to be conquered?
por: Singariya, Geeta, et al.
Publicado: (2023) -
Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
por: Zhou, Nan, et al.
Publicado: (2023) -
Workarounds that work: how to conquer anything that stands in your way at work
por: Bishop, Russell
Publicado: (2011)